The global Cannabis Pharmaceuticals Market, which are pharmaceuticals derived from cannabis, was valued at USD 6.84 billion in 2022 and is expected to grow to USD 1,356.78 billion by 2032 with a CAGR of 80% during the forecast period. The increasing legalization of medical marijuana, rising demand for cannabis-based pharmaceuticals due to their therapeutic benefits, and growing public awareness about the advantages of medical marijuana are driving revenue growth in the market.
Germany, the United States, Canada, and other countries have legalized medical marijuana, and this trend is expected to continue, leading to high demand for cannabis pharmaceuticals and revenue growth.
Get a free sample PDF of the report, visit @
https://www.reportsanddata.com/download-free-sample/6327
The therapeutic benefits of cannabis, including the ability to reduce pain and inflammation, anxiety, and convulsions, are another important factor driving revenue growth in the market. Increasing popularity of cannabis for medical purposes and the creation of innovative cannabis-based products are expected to fuel market expansion.
Key players in the Cannabis Pharmaceuticals Market –
- GW Pharmaceuticals PLC
- Insys Therapeutics, Inc.
- Tilray, Inc.
- Cannabis Science, Inc.
- ABcann Medicinals, Inc.
- Medical Marijuana, Inc.
- Emerald Health Therapeutics, Inc.
- Cannabis Sativa, Inc.
- Cara Therapeutics, Inc.
- Avicanna Inc.
These companies are adopting various strategies such as mergers and acquisitions, partnerships, and the introduction of new products to strengthen their position in the market.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/6327
The market is segmented into three product types: oral, topical, and inhalation. The oral segment accounted for the largest revenue share in 2022, while the topical segment is expected to register significantly rapid revenue growth during the forecast period. The inhalation segment is also expected to register steady fast revenue growth.
Based on therapeutic application, the market is segmented into chronic pain, cancer, multiple sclerosis, and others. The chronic pain segment accounted for the largest revenue share in 2022, while the cancer segment is expected to register significant rapid revenue growth during the forecast period. The multiple sclerosis segment is also expected to register steady fast revenue growth.
Regionally, North America is expected to account for the largest revenue share during the forecast period due to the legalization of cannabis in Canada and a number of U.S. states, the increasing need for cannabis-based medicines, and favorable government initiatives. The market in Europe is expected to register the fastest revenue CAGR during the forecast period due to rising incidence of chronic diseases, an ageing population, and growing public awareness of the potential advantages of cannabis-based medicines. The market in Asia Pacific is expected to account for a significantly large revenue share during the forecast period, driven by favorable government initiatives, rising awareness of the potential advantages of cannabis-based medicines, and rising prevalence of chronic diseases such as cancer.
Request a customized copy of the report @
https://www.reportsanddata.com/request-customization-form/6327
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact:
John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
Browse for more report:
